AP NEWS
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Globe Newswire
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation.

Rubius Therapeutics Announces Poster Presentations at the 2019 American Association for Cancer Research Annual Meeting

February 27, 2019

CAMBRIDGE, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced that the company will present preclinical data from its oncology pipeline of Red Cell Therapeutics™ at the 2019 American Association for Cancer Research (AACR) Annual Meeting. The meeting will be held March 29 - April 3, 2019, at the Georgia World Congress Center in Atlanta.

“Rubius Therapeutics will be presenting preclinical data from our growing oncology pipeline that support two potentially groundbreaking allogeneic, off-the-shelf, cellular immuno-oncology approaches, enabled by our RED PLATFORM®,” said Pablo J. Cagnoni, M.D., chief executive officer of Rubius Therapeutics. “First, we have engineered our Red Cell Therapeutics™ to express, on their surface, combinations of co-stimulatory molecules and cytokines, such as 4-1BBL with IL-15TP or 4-1BBL with IL-12, which are designed to more potently and efficiently activate the adaptive and innate immune systems to attack tumors. Second, and in contrast to adoptive or autologous cell therapy approaches that require engineering the patient’s own T cells, we have created artificial antigen presenting cells (aAPCs) that are designed to induce a tumor-specific immune response and dramatically expand tumor-specific T cells. These T cells are then expected to traffic to tumors and deliver a potent anti-tumor effect. We plan to include significantly updated data in the posters at AACR, demonstrating these two novel approaches with our lead oncology candidates RTX-240 (formerly RTX-212) and RTX-224 for solid tumors and RTX-aAPC for HPV+ tumors.”

Details of the poster presentations are as follows:

Abstract Title: RTX-212, an allogeneic red cell therapeutic expressing 4-1BBL and IL-15TP, exhibits potent in vitro and in vivo activity and a favorable safety profileSession Date and Time: Tuesday, April 2, 2019 from 8:00 a.m. - 12:00 p.m. ETLocation: Exhibit Hall B, Poster Section 25Poster Number: 22Abstract Number: 3272

Abstract Title: RTX-IL-12, an allogeneic red cell therapeutic expressing IL-12, exhibits potent in vitro and in vivo activity and favorable safety profileSession Date and Time: Tuesday, April 2, 2019 from 8:00 a.m. - 12:00 p.m. ETLocation: Exhibit Hall B, Poster Section 25Poster Number: 6Abstract Number: 3256

Abstract Title: Engineered red cell therapeutics (RCT) as artificial antigen presenting cells promote in vivo expansion and anti-tumor activity of antigen specific T cellsSession Date and Time: Tuesday, April 2, 2019 from 8:00 a.m. - 12:00 p.m. ETLocation: Exhibit Hall B, Poster Section 25Poster Number: 10Abstract Number: 3260

About Rubius Therapeutics Rubius Therapeutics is a biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines. The Company’s proprietary RED PLATFORM® is designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent, ready-to-use allogeneic cellular therapies. Rubius is leveraging three distinct therapeutic modalities — cellular shielding, potent cell-cell interaction and tolerance induction for the potential treatment of rare enzyme disorders, cancer and autoimmune diseases. For more information, visit www.rubiustx.com or follow us on Twitter and LinkedIn. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the therapeutic potential of our Red Cell Therapeutics and our strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to the planned timing for our first IND application for RTX-134 for the treatment of phenylketonuria, the safety profile of our Red Cell Therapeutic product candidates, the development of our Red Cell Therapeutic product candidates and their therapeutic potential, whether and when, if at all, our Red Cell Therapeutic product candidates will receive approval form the U.S. Food and Drug Administration and for which, if any, indications, competition from other biotechnology companies, and other risks identified in our SEC filings, including our Form 10-Q for the quarter ended September 30, 2018, and subsequent filings with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent our views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.

Contacts:Lori Melançon Vice President, Corporate Communications and Investor Relations +1 (617) 949-5296 lori.melancon@rubiustx.com Media Contact: Dan Budwick 1AB +1 (973) 271-6085 dan@1abmedia.com